Lattice Health

Lattice Health likely targets radiology departments and health systems through direct enterprise sales, leveraging relationships with radiologists and clinical IT decision-makers. A probable wedge is integration with existing PACS/RIS infrastructure, allowing AI models from multiple vendors to be orchestrated through a single platform. Land-and-expand within health systems as additional imaging modalities and AI models are onboarded could drive meaningful NRR.

Likely a SaaS or platform licensing model charging health systems a subscription or per-seat/per-scan fee to deploy, manage, and monitor clinical AI models across imaging workflows. Additional revenue may come from model marketplace transaction fees or integration services.

Lattice Health is positioning itself as the orchestration and governance layer for clinical AI in medical imaging — essentially middleware that allows hospitals to deploy, manage, and audit multiple AI models across radiology and other imaging workflows without bespoke integrations. This is a credible and timely wedge given the explosion of FDA-cleared imaging AI tools and health systems' struggles to operationalize them at scale. The 'operating system' framing suggests a platform play with strong potential for lock-in if they own the workflow layer. HealthTech is a high-fit sector for Element 14, and AI-native clinical infrastructure aligns well with the fund's thesis. Key risks include long enterprise sales cycles in health systems, heavy compliance overhead (HIPAA, FDA SaMD considerations), and potential competition from EHR giants or PACS vendors expanding into AI orchestration. Founder-market fit and existing health system relationships will be critical proof points to validate before conviction.

Lattice Health fits Element 14's HealthTech and AI-native product thesis well, addressing a real and growing pain point in clinical AI deployment with a platform model that could be highly defensible if distribution is established early. However, health system sales cycles are notoriously long and capital-intensive, which creates tension with the fund's preference for capital-efficient, near-default-alive companies. Insufficient information on founder background and current traction limits full conviction, but the market timing and thesis alignment are directionally strong.